You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

998 Results
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
Exceptional Access Program
    cabozantinib – For the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma, in combination with nivolumab, according to clinical criteria
New Drug Funding Program
    Nivolumab - In Combination with Cabozantinib for First Line Advanced or Metastatic Renal Cell Carcinoma
Nov 2024
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Completely Resectable Stage III or IV Melanoma
Oct 2024
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2024
Regimen
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Tebentafusp (Outpatient) - Unresectable or Metastatic Uveal Melanoma
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
Exceptional Access Program
    cabozantinib - For the treatment of advanced renal cell carcinoma (RCC), based on criteria
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
Exceptional Access Program
    cabozantinib - For the treatment of unresectable, advanced hepatocellular carcinoma (HCC), based on criteria

Pages